CurrentCapital BluecrossPolicy AHS - G2045 - Thyroid Disease Testing

Thyroid Disease Testing

Defines coverage criteria and limitations for laboratory testing of thyroid function, antibodies, and related assays across clinical scenarios (hypothyroidism, hyperthyroidism, pregnancy, pediatric, monitoring, screening, and thyroid cancer surveillance). Applies to tests such as TSH, fT4, fT3, TT3, TT4, thyroid antibodies, thyroglobulin, and certain excluded tests.

Policy Summary

PayerCapital Bluecross

PolicyThyroid Disease Testing

Policy CodePolicy AHS - G2045 - Thyroid Disease Testing

Change TypeRevision Date updated

Effective DateMar 19, 2015

Next Review Date

Key ActionWhen testing pregnant individuals, perform assays only at labs that have trimester-specific normal ranges for their assays; prefer fT4 but use TT4 if fT4 ranges unavailable or discordant.

POLICY UPDATE CHANGES

Revision Date updated to 07/01/2025 in header.

MultipleCovered test categories

SeveralNot covered test categories

4 wksPregnancy monitoring interval

MultipleGuidelines referenced

16Procedure codes listed

Coverage Summary

Policy: AHS - G2045 - Thyroid Disease Testing (status: CURRENT). Effective/Initial: 03/19/2015; Last review/Revision Date: 07/01/2025. Subject: Thyroid Disease Testing. Coverage stance: mixed — the document defines specific situations where testing MEETS coverage criteria and lists tests/uses that DO NOT meet criteria.

Scope summary and high-level coverage: the policy covers routine and targeted laboratory testing of thyroid function (primarily TSH, fT4, fT3/TT3), thyroid autoantibodies (e.g., TPOAb, Tg‑Ab, TRAb/TSH‑R‑Ab), and thyroglobulin for differentiated thyroid cancer surveillance when indicated. It also specifies excluded tests and circumstances not meeting coverage (TRH, TBG, reverse T3, T3 uptake, certain TT4/TT3 uses).

Covered vs not covered mapping (brief): Covered categories include TSH as first‑line screening, reflex or follow-up fT4 (and fT3/TT3 when hyperthyroidism suspected), thyroid antibodies in selected circumstances, and thyroglobulin/Tg‑Ab for thyroid cancer surveillance. Not covered categories include TRH, TBG, reverse T3, T3 uptake, and routine TT3/fT3 testing for hypothyroidism dose assessment or nonindicated asymptomatic screening.

Key thresholds & targets

Pregnancy monitoring intervalTSH and fT4 testing once every 4 weeks for pregnant/postpartum individuals with symptoms

Hypothyroidism dosing change monitoringTSH and fT4 every 6 weeks upon dosage change

Secondary hypothyroidism dosing change monitoringfT4 every 6 weeks upon dosage change

Immune reconstitution therapy (IRT) monitoringTSH once every 3 months with reflex fT4 and fT3 when abnormal

TSH stabilization definition2 similar measurements within the reference range 3 to 6 months apart

Post-antithyroid drug monitoring (adults) after stoppingTSH within 8 weeks, then every 3 months for 1 year, then annually

Medical-Necessity Criteria

Medically Necessary / Meets Coverage Criteria

The following tests MEET COVERAGE CRITERIA when the stated clinical conditions are present or monitoring intervals are indicated.

Indications for thyroid testing (general)
- Individuals with signs and symptoms consistent with hypothyroidism (see Note 1): TSH testing to confirm or rule out primary hypothyroidism.
- Free T4 (fT4) testing as a follow up to abnormal TSH finding.
- TSH and fT4 testing in cases of suspected secondary (central) hypothyroidism.
- Individuals with signs and symptoms consistent with hyperthyroidism (see Note 2): TSH testing to confirm or rule out overt hyperthyroidism.

Indications, Screening & Initial Testing

Initial diagnostic test and reflex testing

Suggested test cascade when evaluating thyroid function:

TSH is the first-line screening test for most patients (ACOG, ATA, ATA/AACE, AAFP, ASCP).
Reflex/additional testing depending on result
- If TSH above reference range → measure FT4 (NICE).
- If TSH below reference range → measure FT4 and FT3 (NICE; consider TT3, TRAb in pregnancy or suspected hyperthyroidism).
- If pituitary disease suspected → measure both TSH and FT4 in same sample (NICE, ETA).

Pregnancy-Specific Thresholds & Monitoring

Pregnancy-specific thresholds and monitoring

For pregnant or postpartum individuals, thyroid testing and monitoring must account for physiologic changes of pregnancy and use assays with trimester-specific reference ranges.

Use trimester-specific reference ranges for all assays used during pregnancy; laboratories must report trimester-specific normal ranges for TSH and for fT4 (or TT4 if fT4 ranges unavailable).

TSH is the recommended initial screening test in pregnancy; reflex testing to fT4 should occur with abnormal TSH.

Documentation Required

Documentation: pregnancy testing and monitoring

Use trimester-specific reference ranges when testing pregnant or postpartum individuals; prefer fT4 for evaluation and monitoring in pregnancy; use TT4 only if trimester-specific fT4 ranges are unavailable or when results are discordant. Monitoring frequency: test every 4 weeks during pregnancy when symptomatic or being treated, resume standard 6-week interval after dose changes and annual testing when stable. Coverage and denials: coverage is dependent on member benefits; tests that do not meet the criteria or are performed without required trimester-specific reference ranges may be denied.

Monitoring Intervals & Follow-up

Monitoring intervals for specific scenarios (NICE/ATA/ETA)

Recommended testing frequency for management and follow-up:

Adults on levothyroxine
- Measure TSH every 3 months until stable (two similar measurements within reference range 3 months apart), then annually (NICE).TSH every 3 months until stable; then annual
Children >=2 years on levothyroxine
- Measure FT4 and TSH every 6-12 weeks until TSH stabilized, then every 4-6 months until after puberty, then annually (NICE).6-12 weeks then 4-6 months then annual
Children <2 years on levothyroxine

Antibody Testing & Special Assays

Testing for antibodies and special tests

When to measure thyroid autoantibodies and special assays:

Consider TPOAb measurement when evaluating patients with subclinical hypothyroidism (ATA/AACE).
Consider TPOAb in evaluation of recurrent miscarriage regardless of fertility (ATA/AACE).
Measure TRAb in pregnant patients with history of Graves' disease treated with radioactive iodine or thyroidectomy; consider TRAb at 20-26 weeks and repeat if elevated (ATA).TRAb at 20-26 weeks; repeat if elevated
ETA: measure TSH-R-stimulating antibody (TSH-R-Ab) for diagnosis and monitoring of Graves' disease and before stopping ATD.

Thyroid Cancer Surveillance

Individuals with thyroid cancer

For individuals with thyroid cancer and post-surgical surveillance:

Testing for serum thyroglobulin and/or Tg-Ab levels for detection of tumor recurrence, post-surgical evaluation, surveillance, and maintenance for differentiated thyroid carcinomas meets coverage criteria.
In pregnancy, for differentiated thyroid cancer, target TSH 0.1-1.5 mIU/L and monitor every 4 weeks until 16-20 weeks then as recommended (ATA).TSH 0.1-1.5 mIU/L; monitor every 4 weeks until 16-20 weeks

Thyroglobulin and Tg‑Ab are used as biomarkers in the detection and surveillance of differentiated thyroid carcinoma: serum thyroglobulin (and measurement of Tg‑Ab) is indicated for post‑surgical evaluation, tumor recurrence detection, and ongoing surveillance/maintenance. Autoantibodies can also be present in patients with thyroid cancer and may affect interpretation of Tg assays, so concomitant Tg‑Ab measurement is often used to interpret thyroglobulin results.

Not Covered / Experimental Tests

Not Covered / Does Not Meet Coverage Criteria

The following tests DO NOT MEET COVERAGE CRITERIA:

Testing for thyrotropin-releasing hormone (TRH) or thyroxine-binding globulin (TBG) for evaluation of cause of hyperthyroidism or hypothyroidism.
Testing of reverse T3, T3 uptake, and TT4 for all other situations not mentioned above.
Measurement of TT3 and/or fT3 for the assessment of hypothyroidism.
Measurement of total or fT3 level to assess levothyroxine dose in hypothyroid patients.
Testing for thyroid dysfunction during a general exam in asymptomatic nonpregnant individuals without abnormal findings.

Coding

Thyroid-related CPT/HCPCS procedure codes listed in policyCPT

80438	Thyrotropin-releasing hormone (TRH) stimulation panel; 1 hour (must include TSH (84443 x 3))
80439	Thyrotropin-releasing hormone (TRH) stimulation panel; 2 hour (must include TSH (84443 x 4))
83519	Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, by radioimmunoassay (eg, RIA)
83520	Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified
84432	Thyroglobulin
84436	Thyroxine; total
84439	Thyroxine; free
84442	Thyroxine-binding globulin (TBG)
84443	Thyroid stimulating hormone (TSH)
84445	Thyroid stimulating immune globulins (TSI)

1–10 of 16

1/2

Applicable CPT/HCPCS (referenced section present but specific codes not in this part)mixed

No codes listed

Provider Actions & Billing Rules

Documentation Required

Assess thyroid/adrenal function in mitochondrial disease during critical illness (codes 84443, 84439, 84432)

Assess thyroid and adrenal function in critically ill patients with primary mitochondrial disease and include annual screening per recommendations; document and use appropriate testing codes.

Affected codes: 84443, 84439, 84432

Background, Evidence & Definitions

Background rationale: Current assays for TSH are highly sensitive and are the most useful initial test to detect thyroid dysfunction; if TSH is normal usually no further testing is needed. When TSH is high, fT4 distinguishes overt from subclinical hypothyroidism; when TSH is low, fT4 and fT3 (or TT3) help characterize hyperthyroidism. Pregnancy alters thyroid physiology (higher total T4/T3, increased TBG, lower first‑trimester TSH due to hCG), so trimester‑specific and method‑specific reference ranges are required and fT4 is preferred (with TT4 or FT4 index as alternatives when fT4 ranges are unavailable).

Thyroid autoantibodies (e.g., TPOAb, Tg‑Ab, TRAb/TSH‑R‑Ab) are used to evaluate autoimmune thyroiditis, guide management in pregnancy (TRAb to assess fetal/neonatal risk in Graves’ disease), and are considered in workup of subclinical hypothyroidism or recurrent pregnancy loss. Assay analytic validity varies by method—modern chemiluminometric TSH assays have detection limits ~0.01 mU/L and immunoassays for T3/T4 may differ from LC/MS/MS—so assay selection, interference (e.g., biotin), and lab‑specific reference ranges affect test interpretation and utility.

Source	Key point
USPSTF recommendation	Current evidence insufficient to assess screening for thyroid dysfunction in nonpregnant, asymptomatic adults; recommends against screening for thyroid cancer in asymptomatic adults.
ACOG (June 2020)	Universal screening in pregnancy not recommended; TSH is first-line screening test; monitor TSH in pregnant individuals treated for hypothyroidism with target TSH between lower reference limit and 2.5 mIU/L and testing every 4-6 weeks while adjusting therapy.
Cohort meta-analysis (Korevaar/Toloza et al.)	Meta-analysis/cohorts of pregnant individuals (46,528; 39,826 classified) found subclinical hypothyroidism prevalence 3.2% and associations between thyroid dysfunction and adverse pregnancy outcomes (eg, pre-eclampsia, preterm birth).
NICE NG145 (2023)	Recommends initial testing with TSH alone when secondary thyroid dysfunction not suspected, with reflex FT4/FT3 per TSH result; details monitoring intervals and consideration of TSH/FT4 testing frequency across ages and treatments.
SMFM (Soc Maternal-Fetal Medicine)	Recommends against screening asymptomatic pregnant individuals for subclinical hypothyroidism.
Mitochondrial Medicine Society (MMS)	Recommends assessment of thyroid and adrenal function during critical illness and consideration of annual screening (including TSH, FT4) in individuals with primary mitochondrial disease; annual screening recommended for those with mtDNA deletions.

Term	Definition
fT4	Free thyroxine (free T4). Used to assess thyroid hormone levels; preferred in pregnancy when method- and trimester-specific ranges available; TT4 may be used if unavailable.
fT3	Free triiodothyronine (free T3). Measured when hyperthyroidism is suspected; not routinely recommended for monitoring levothyroxine therapy.
TSH	Thyroid stimulating hormone; first-line screening test for thyroid dysfunction; most sensitive initial test.
TT3	Total T3. May be measured to evaluate hyperthyroidism; measurement generally not indicated for assessment of hypothyroidism or levothyroxine dosing.
TT4	Total T4. Total thyroxine; may be useful in pregnancy with pregnancy-adjusted reference ranges or when fT4 assay ranges unavailable or discordant.
TPOAb	Thyroid peroxidase antibody; considered in evaluation of subclinical hypothyroidism and recurrent miscarriage; may guide monitoring in pregnancy.
Tg-Ab	Antithyroglobulin antibody; used in thyroid cancer surveillance and considered in miscarriage evaluation; measured with thyroglobulin for cancer surveillance.
TRAb / TSH-R-Ab	Thyrotropin receptor antibody (also TSH-R-stimulating antibody). Measured in Graves' disease and in pregnancy to assess fetal/neonatal risk; obtain in early pregnancy and around 20-26 weeks if indicated.

Revision History

2015-03-19effective

Policy effective date as shown in document header

2025-07-01last_reviewLatest

Policy last review date as shown in document header

2025-07-01revision

Revision Date updated to 07/01/2025 in header

Policy Summary

PayerCapital Bluecross

PolicyThyroid Disease Testing

Policy CodePolicy AHS - G2045 - Thyroid Disease Testing

Change TypeRevision Date updated

Effective DateMar 19, 2015

Next Review Date

Key ActionWhen testing pregnant individuals, perform assays only at labs that have trimester-specific normal ranges for their assays; prefer fT4 but use TT4 if fT4 ranges unavailable or discordant.

On This Page

fT4 testing as a follow up to abnormal TSH findings.

Total T3 (TT3) or free T3 (fT3) testing to confirm a diagnosis of hyperthyroidism when T3 toxicosis is suspected.

fT4 testing to help distinguish between overt and subclinical hyperthyroidism.

Individuals with a thyroid nodule.

Individuals capable of becoming pregnant who have experienced two or more pregnancy losses.

Individuals with disease or neoplasm of the thyroid or other endocrine glands.

Individuals with chronic or acute urticaria.

Pediatric individuals diagnosed with short stature or failure-to-thrive.

Individuals following allogeneic bone marrow transplantation (BMT) or hematopoietic stem cell transplantation (HSCT).

Individuals undergoing immune reconstitution therapy (IRT) (see monitoring frequency node).

Indications for thyroid testing (pregnancy)

Pregnant or postpartum individuals with symptoms of thyroid dysfunction: TSH and fT4 testing once every 4 weeks during pregnancy/postpartum (perform testing only at labs with trimester-specific reference ranges).
Pregnant or postpartum individuals diagnosed with hyperthyroidism: TT4, Tg-Ab, TRAb, and TPOAb testing as clinically indicated.

Screening recommendations for asymptomatic individuals

One-time TSH screening is covered for asymptomatic individuals at high risk for thyroid disease due to personal or family history of thyroid dysfunction, personal or family history of type 1 diabetes or other autoimmune disease.
One-time TSH screening is covered for individuals with disease or neoplasm of the thyroid or other endocrine glands, individuals with chronic or acute urticaria, and select pediatric indications (short stature, failure-to-thrive).
Routine screening of asymptomatic nonpregnant individuals during a general exam without abnormal findings DOES NOT MEET COVERAGE CRITERIA (see Not Covered group).

Investigation of abnormal tests

Reflex fT4 (and fT3 when indicated) when TSH is abnormal to differentiate overt versus subclinical disease and guide management.
Measurement of thyroid antibodies (Tg-Ab, TPOAb, TRAb, TSI) is covered: testing once every three years for individuals with hypothyroidism or hyperthyroidism; and for pregnant/postpartum individuals with hyperthyroidism as indicated.

Monitoring frequency after treatment

For individuals being treated for primary hypothyroidism: monitoring with TSH and fT4 every 6 weeks after a levothyroxine dosage change, and annually in stable individuals.
For individuals being treated for secondary hypothyroidism: monitoring with fT4 every 6 weeks after dosage change, and annually in stable individuals.
For patients being treated for hyperthyroidism: repeat testing of TSH and fT4 every 6 weeks during treatment; annual monitoring after the first year even if asymptomatic for risk of relapse or late-onset hypothyroidism.

Monitoring for subclinical hyperthyroidism

fT4 testing to distinguish overt from subclinical hyperthyroidism; follow-up and monitoring intervals as clinically indicated (covered testing for initial evaluation and subsequent monitoring per treatment guidance).

Monitoring in mitochondrial disease

Annual screening of TSH and fT4 for individuals diagnosed with primary mitochondrial disease.

For individuals on medications that can interfere with thyroid function: TSH testing annually, when medication dosage changes, and whenever symptoms consistent with thyroid dysfunction develop.

Not Covered / Does Not Meet Coverage Criteria

The following tests DO NOT MEET COVERAGE CRITERIA:

Measurement of thyrotropin-releasing hormone (TRH) and thyroxine-binding globulin (TBG) for evaluation of the cause of hyperthyroidism or hypothyroidism.
Testing of reverse T3, T3 uptake, and total T4 (TT4) in situations not otherwise specified as covered.
Measurement of TT3 and/or fT3 for assessment of hypothyroidism (not indicated for routine hypothyroidism assessment).
Measurement of total or free T3 to assess levothyroxine dose in hypothyroid patients.
Testing for thyroid dysfunction in asymptomatic nonpregnant individuals during a general exam without abnormal findings (routine population screening).

Pregnancy considerations

In pregnancy, measure FT4 using method-specific and trimester-specific reference ranges; when unavailable, TT4 with pregnancy-adjusted range or FT4 index may be used (ATA).
Avoid routine measurement of total/free T3 when not indicated; T3 testing recommended when suspecting thyrotoxicosis.

Procedural cascade: TSH is recommended as the first-line screening test for most patients. If TSH is above the reference range, obtain fT4 on the same sample. If TSH is below the reference range, obtain fT4 and fT3 (or TT3 where indicated, e.g., pregnancy or suspected hyperthyroidism). In suspected pituitary/hypothalamic disease measure TSH and fT4 together.

In pregnancy use assay‑ and trimester‑specific reference ranges and prefer fT4; when trimester‑specific fT4 ranges are unavailable or results are discordant, consider TT4 (with pregnancy‑adjusted range) or FT4 index.

Labs must provide trimester-specific reference ranges for TSH and fT4 (or TT4 if fT4 ranges unavailable).
TSH should be used as the initial test and reflex to fT4 when abnormal.
Antibody testing (TPOAb, Tg-Ab, TRAb) is covered in pregnancy when clinically indicated (e.g., hyperthyroidism or suspected autoimmune disease).
Monitoring after therapies (e.g., antithyroid drugs, radioiodine, surgery) should follow the policy intervals: every 6 weeks during dose titration and annually once stable, with more frequent monitoring during pregnancy.

Measure FT4 and TSH every 4-8 weeks until stabilized, then every 2-3 months first year, every 3-4 months second year (NICE).4-8 weeks then 2-3 months then 3-4 months

After radioactive iodine

Measure fT3, fT4, and TSH every 6 weeks for first six months; then monitor at 9 and 12 months and every 6 months thereafter if stable (NICE).every 6 weeks x6 months; then 9 and 12 months; then every 6 months

Antithyroid drug therapy

Measure TSH, FT4, FT3 every 6 weeks until TSH normalized; then TSH every 3 months until drugs stopped (NICE).every 6 weeks until normalized; then every 3 months

ETA after alemtuzumab

After alemtuzumab, biochemical follow-up with TSH every 3 months for 4 years after last treatment (ETA).TSH every 3 months for 4 years

Recommended monitoring cadence (summary): For adults on levothyroxine, measure TSH every 3 months until levels are stable (defined as two similar measurements within the reference range 3 months apart), then annually. For children on levothyroxine, follow age‑based intervals: children ≥2 years every 6–12 weeks until TSH stabilizes then every 4–6 months until after puberty (with more frequent testing <2 years: every 4–8 weeks until stable).

After radioactive iodine therapy monitor fT3, fT4, and TSH every 6 weeks for the first 6 months, then at 9 and 12 months and every 6 months thereafter if stable. For antithyroid drug therapy monitor TSH, fT4, and fT3 every 6 weeks until TSH normalizes, then TSH every 3 months until drugs stopped. Following alemtuzumab (immune reconstitution therapy) perform biochemical follow-up with TSH every 3 months and continue routine three‑monthly monitoring for 4 years after last treatment.

Routine measurement of thyroid autoantibodies is not recommended in euthyroid patients during surveillance (ETA).

Routine measurement of calcitonin in pregnant women with thyroid nodules: utility unknown; cannot recommend for or against (ATA).

Documentation Required

Obtain TRAb in pregnant patients with history of Graves’ disease; consider TPOAb in subclinical hypothyroidism or recurrent miscarriage

Obtain thyrotropin receptor antibody (TRAb) testing in pregnant patients with a history of Graves' disease (including those treated with radioactive iodine or thyroidectomy). Per guideline timing, obtain TRAb in early pregnancy or at 20–26 weeks, and if elevated or if the patient is on antithyroid drugs in the third trimester, repeat testing at 30–34 weeks. Consider testing antithyroid peroxidase antibody (TPOAb) when evaluating subclinical hypothyroidism or recurrent miscarriage.

Obtain TRAb at 20–26 weeks (or during first trimester) and repeat at 30–34 weeks if elevated or if on antithyroid drugs in third trimester.
Consider TPOAb testing in evaluation of subclinical hypothyroidism or recurrent pregnancy loss.

Denial Risk

Tests not meeting coverage may be denied

Claims for noncovered or nonindicated thyroid tests may be denied.

Thyrotropin-releasing hormone (TRH) testing
Thyroxine-binding globulin (TBG) testing
Reverse T3 (rT3) testing
T3 uptake testing
Total or free T3 (TT3/fT3) when used to assess hypothyroidism or levothyroxine dosing
Routine thyroid screening in asymptomatic, nonpregnant individuals without abnormal findings